



**4<sup>TH</sup> CANADIAN CLL MEETING**  
**Winnipeg, Manitoba**  
**October 2<sup>ND</sup> & 3<sup>RD</sup>, 2008**

**AGENDA**

**Thursday, October 2<sup>nd</sup>, 2008**

- 7:30 – 8:15 am            Breakfast
- 8:15 – 8:30 am            Welcoming Address  
*Spencer Gibson*
- 8:30 – 9:30 am            **Keynote Address**  
**Prognostic Markers in CLL - An Update**  
***Neil Kay***  
***Mayo Clinic, Rochester, MN***

***Session I – Clinical Trials***  
***Chair: Chaim Shustik***

- 9:30 – 9:50 am            Clonal B-Cell Lymphocytosis of Undetermined Significance  
*Chen Wang*
- 9:50 – 10:10 am            ***DISCUSSION***
- 10:10 – 10:30 am            Optimum Measurement of Minimal Residual Disease  
*Carmen Morales*
- 10:30 – 11:00 am            COFFEE
- 11:00 – 11:30 am            Utility of Genetic Testing in CLL  
*Janette van den Berghe*
- 11:30 am – 12:00 pm        New Therapies for CLL  
*Christine Chen*
- 12:00 – 1:00 PM            LUNCH



**Session II – Stem Cell Marrow Transplantation in CLL**  
**Chair: Stephen Couban**

- |                |   |
|----------------|---|
| 1:00 - 1:30 pm | Alemtuzumab Experience in British Columbia & Manitoba<br><i>Marc Geirnaert</i>  |
| 1:30 – 2:00 pm | CALGB 10401: A Randomized Phase II Study of 3<br>Fludarabine/Antibody Combinations for Patients with<br>Symptomatic Previously Untreated CLL<br><i>Mike Voralia</i> |
| 2:00 – 2:30 pm | CALGB 10501: Early Intervention for Asymptomatic CLL<br><i>Matthew Seftel</i>   |
| 2:30 – 3:00 pm | COFFEE  |
| 3:00 – 3:30 pm | Is “Intensity” Important in the Conditioning Regimen in<br>an Allogeneic Stem Cell Transplant for CLL?<br><i>Mitch Sabloff</i>                                      |
| 3:30 – 4:00 pm | Co-Morbidities Following SCT for CLL<br><i>Cindy Toze</i>   |
| 4:00 – 4:45 pm | Randomized Phase II Study between Reduced Intensity<br>Myeloablative and Non-Myeloablative Allogeneic SCT for<br>CLL: An NCIC CTG Proposal<br><i>Matthew Seftel</i> |
| 7:00 pm        | Dinner<br><i>The Current Restaurant</i><br><i>Inn at the Forks</i>  |

**Friday, October 3<sup>rd</sup>, 2008**

8:00 – 8:30 am Breakfast

***Session III – Basic Research in CLL***  
***Chair: David Spaner***

8:30 – 9:00 am TBA  
*David Spaner*

9:00-9:30 am New Therapies for CLL  
*Raquel Aloyz*

9:30 - 10:00 am Importance of Lipid Rafts for Death Receptor Function in CLL  
*Spencer Gibson*

10:00 - 10:30 am COFFEE

10:30 – 11:00 am A Novel Non-Competitive Proteasome Inhibitor for Refractory Hematological Malignancies Including CLL  
*Aaron Schimmer*

11:00 – 11:30 am Tumor Banking for CLL in Canada: An Update  
*Spencer Gibson*

11:30 am – 12:00 pm Why do Elderly Men with CLL have Such a Poor Prognosis?  
*James Johnston*

12:00 – 12:10 pm Concluding Remarks

12:10 pm LUNCH